Tags Archives: VA-ECMO

Perfusfind S.L.

Abstract Weaning and liberation from V-A ECMO for cardiogenic shock involves complex decision-making that requires balancing multiple clinical parameters. In the absence of specific weaning guidelines, ECMO centers rely on..

Perfusfind S.L.

Abstract Objectives Hemorrhagic complications remain a major concern in patients with cardiogenic shock and extracorporeal cardiopulmonary resuscitation. The purpose of this study was to assess the effect of withholding a..

Perfusfind S.L.

Abstract Background Veno-arterial ExtraCorporeal Membrane Oxygenation (V-A ECMO) as a bridge to recovery or long-term assist devices in severe cardiocirculatory failure typically lasts 5–7 days. There is scarce guidance on..

Perfusfind S.L.

Abstract Background Subclavian or axillary artery cannulation for venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides a valuable alternative to femoral access; however, a comprehensive overview of such an approach in this..

Perfusfind S.L.

Abstract This study aimed to investigate the heterogeneity of treatment effect for intra-aortic balloon pump (IABP) across various lactate trajectories in patients with acute myocardial infarction-related cardiogenic shock (AMICS) supported..

Perfusfind S.L.

Abstract Limb ischemia is the most common vascular complication in patients receiving femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) and is associated with an increased risk of mortality., To improve blood flow..

Perfusfind S.L.

Abstract Introduction: Weaning from venoarterial extracorporeal membrane oxygenation (VA ECMO) remains a major challenge because reliable indicators of cardiac recovery are lacking. Arterial pulse pressure (PP), a simple and continuously measured..

Perfusfind S.L.

Abstract This retrospective single-center study evaluated adults with cardiogenic shock supported with veno-arterial extracorporeal membrane oxygenation (VA ECMO) from 2011 to 2023 to identify predictors of in-hospital mortality among those..

Perfusfind S.L.

Abstract Background Data on the outcome of veno-arterial extracorporeal membrane oxygenation (V-A-ECMO) support as a bridge to replacement therapies are scarce. Objectives We investigated the outcome of V-A-ECMO support after..

Perfusfind S.L.

Abstract Background Despite advances in cardiopulmonary resuscitation (CPR), survival after out-of-hospital cardiac arrest (OHCA) remains low. Use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) as extracorporeal CPR (ECPR) may improve..

Perfusfind S.L.

Abstract Ventricular septal rupture (VSR) is a rare but often fatal complication of acute myocardial infarction (AMI), with a high mortality largely driven by resultant cardiogenic shock. Venoarterial extracorporeal membrane..

Perfusfind S.L.

Abstract Introduction:  In cardiogenic shock (CS), persistent microcirculatory impairment despite improved macrocirculatory parameters is associated with poor outcomes. Therapeutic strategies must therefore address both macro- and micro-circulation. Conventional microcirculatory measures..

Perfusfind S.L.

Abstract Importance To date, no studies have described the financial burden and behaviors of left ventricular mechanical unloading (LVMU) for patients on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Given the..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-saving intervention for individuals with refractory cardiopulmonary failure and is associated with several complications. Differential hypercapnia, also known as RIDDLER syndrome or..

Perfusfind S.L.

Abstract Background Major bleeding is a common and serious complication of veno-arterial extracorporeal membrane oxygenation (VA ECMO). Current perspectives on bleeding risk fail to reflect dynamic changes over time in..

Perfusfind S.L.

Abstract Background and Objective Venoarterial extracorporeal membrane oxygenation (VA ECMO) circuits typically utilise a continuous flow (CF) of blood to support patients suffering from refractory cardiorespiratory dysfunction. Pulsatile flow (PF)..

Perfusfind S.L.

Abstract Background The prognostic significance of an adverse acid–base milieu despite venoarterial extracorporeal membrane oxygenation support in patients with cardiogenic shock remains poorly defined. We examined metabolic and respiratory disturbances..

Perfusfind S.L.

Abstract Background: Hyperoxia induces oxidative stress and can exacerbate inflammatory response to Veno-Arterial Extracorporeal Life Support (VA–ECLS). This study aimed to evaluate the association between hyperoxia during VA–ECLS and morbidity, complications,..

Perfusfind S.L.

Abstract Background The hemodynamic effects of femoro-femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO) on pulmonary capillary wedge pressure (PCWP) remain poorly defined. High ECMO flow is believed to increase PCWP..

Perfusfind S.L.

Abstract The drainage cannula in a venoarterial extracorporeal membrane oxygenation (VA ECMO) circuit transfers venous blood from the patient to a pump. However, drainage cannulas are prone to thrombosis, leading..

Perfusfind S.L.

Abstract Post-cardiotomy cardiogenic shock (PC-CS) affects 2–6% of cardiac surgery patients. While survival rates keep improving, 40% of intensive care (ICU) survivors experience a “post-intensive care syndrome”, encompassing physical, cognitive,..

Perfusfind S.L.

Abstract Introduction Regional citrate anticoagulation (RCA) is the recommended first-line strategy for continuous renal replacement therapy (CRRT) circuits. Acute kidney injury is common in patients undergoing venoarterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Introduction Regardless of its effectiveness, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support is not a risk-free method. Its use is associated with high complication and mortality rates, especially in patients..

Perfusfind S.L.

Abstract Background Fulminant myocarditis is a severe cardiac condition characterized by rapid progression and high mortality. In recent years, advancements in medical technology, particularly the application of mechanical circulatory support,..

Perfusfind S.L.

Abstract Background For patients presenting with cardiogenic shock due to acute myocardial ischaemia, veno-arterial extracorporeal membrane oxygenation (ECMO) is often the only potential lifesaving intervention remaining when revascularisation does not..

Perfusfind S.L.

Abstract Objective(s) To evaluate survival outcomes and identify candidate profiles for venoarterial extracorporeal membrane oxygenation in adult patients with sepsis-induced cardiomyopathy. Design The authors systematically searched PubMed, Embase, and Google..

Perfusfind S.L.

Abstract Background: Veno-arterial ExtraCorporeal Membrane Oxygenation (V-A ECMO) as a bridge to recovery or long-term assist devices in severe cardiocirculatory failure typically lasts 5-7 days. There is scarce guidance on..

Perfusfind S.L.

Abstract Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly utilised in critically ill patients with severe cardiac failure and cardiac arrest, yet sex-specific differences in presentation, utilisation, and clinical outcomes..

Perfusfind S.L.

Abstract Background: Temporary mechanical circulatory support (t‑MCS) is increasingly used in fulminant myocarditis (FM), yet long‑term outcomes and risk factors remain poorly defined.   Methods: From the FULLMOON international cohort..

Perfusfind S.L.

Abstract Background: Harlequin syndrome, also referred to as differential hypoxemia or North South syndrome, is a critical yet underrecognized complication of venoarterial extracorporeal membrane oxygenation and hybrid configurations such as ECpella...